Stay updated on FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The study record for the derazantinib and atezolizumab urothelial cancer trial is displayed, including its design, participant criteria, study locations, and outcome measures.
    Difference
    85%
    Check dated 2026-11-09T14:57:09.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-02T16:33:11.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    A sitewide NIH notice about website updates and terminology appears above the unchanged 403 Forbidden page.
    Difference
    1%
    Check dated 2026-10-26T16:45:28.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The footer revision number changes from v3.7.1 to v3.7.2 while the page continues to show a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-19T21:56:21.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.7.1 instead of v3.7.0, while the page continues to show a 403 error.
    Difference
    0.2%
    Check dated 2026-10-13T04:15:00.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error, replacing the normal study details with a simple error page.
    Difference
    18%
    Check dated 2026-09-21T22:30:31.000Z thumbnail image

Stay in the know with updates to FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page.